However, even if the two studies contain 70% of cases with RUNX1 mutations, the American cohort contains mostly secondary monocytic pDC-AML, and a minority of undifferentiated AML, whereas the French cohort contains mainly M0-AML. Here, RUNX1 is linked to acute myeloid leukemia.